乐伐替尼

Name: 乐伐替尼
Brand: 济南圣和化工有限公司

CAS 417716-92-8C21H19ClN4O4MW 426.9

乐伐替尼（CAS 417716-92-8）属有机化学品类产品，分子式 C21H19ClN4O4，分子量 426.9。济南圣和化工有限公司常年现货供应该产品，常规纯度按批次COA提供(不公开发布)，可按客户需求安排分装包装，欢迎邮件或来电询价。

产品概览

CAS号	417716-92-8
分子式	C21H19ClN4O4
分子量	426.9
LogP	3.3
纯度	按批次COA提供(不公开发布)
包装	按订单/批次确认(不公开发布)
应用领域	有机化学品
类别	有机化学品

应用领域

有机化学品

该产品的下游应用集中在有机化学品。不同客户工艺差异较大，我们支持按需提供样品与小批量试用。

包装与储存

包装规格按订单/批次确认(不公开发布)

纯度规格按批次COA提供(不公开发布)

储存条件密封、阴凉干燥处保存

运输常规化工运输

样品可协商提供

交期现货/按订单安排

供货能力：乐伐替尼备有现货，包装形式为按订单/批次确认(不公开发布)。我们支持对公转账并开具增值税发票，山东省内可安排快速配送，省外按物流时效发货，具体请联系 info@591daili.com。

质量与文件

每批产品随货提供 COA（分析证书）；可按需提供 MSDS/技术数据表及第三方检测报告。纯度与包装以批次 COA 及订单确认为准。

关于供应商

作为化工原料供应服务商，济南圣和化工有限公司长期服务于化工贸易、食品添加、医药中间体、日化原料等行业的采购需求。除乐伐替尼外，您还可以在站内按 CAS 号或产品分类检索更多品类，获取规格与报价。

常见问题

乐伐替尼的 CAS 号是多少？

乐伐替尼的 CAS 号为 417716-92-8。

该产品的纯度和包装规格是什么？

常规纯度规格为按批次COA提供(不公开发布)，包装为按订单/批次确认(不公开发布)，随货提供 COA。

乐伐替尼有什么用途？

主要应用于有机化学品。

如何购买或获取报价？

请发送邮件至 info@591daili.com 或通过 WhatsApp 联系，注明产品名称、CAS 号与需求数量，一个工作日内回复报价。供应商：济南圣和化工有限公司。

PubChem 公开数据

Description

Lenvatinib · CAS 417716-92-8 · C21H19ClN4O4. UNII EE083865G2. LogP: 3.3; Dissociation Constants: 5.05.

Identification

CAS Registry Number	417716-92-8
PubChem CID	9823820
Molecular formula	C21H19ClN4O4
IUPAC name	4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
UNII (FDA)	EE083865G2

Computed Descriptors

Molecular Weight	426.9
XLogP3	2.8
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	6
Exact Mass	426.1094828
Monoisotopic Mass	426.1094828
Topological Polar Surface Area	116
Heavy Atom Count	30
Formal Charge	0

Physical & Chemical Properties

LogP	3.3
Dissociation Constants	5.05

Physical description & handling notes

Based on x-ray crystallography and kinetic interaction studies, lenvatinib binds to the adenosine 5'-triphosphate binding site of VEGFR2 and to a neighbouring region via a cyclopropane ring and thereby inhibits tyrosine kinase activity and associated signalling pathways.

GHS Hazard Classification

Reported hazard statements	H302 (50%), H315 (50%), H319 (50%), H335 (50%), H361 (50%)

H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]

H315 (50%): Causes skin irritation [Warning Skin corrosion/irritation]

Documented Uses

Lenvatinib is indicated for the treatment of the following cancerous conditions: **Differentiated Thyroid Cancer (DTC)** - Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer **Renal Cell Carcinoma (RCC)** - First-line treatment, in combination with [pembrolizumab], in adult patients with advanced renal cell carcinoma (RCC) - Treatment of advanced renal cell carcinoma, in combination with [everolimus], in adult patients who have previously tried ≥1
Lenvatinib is a multiple receptor tyrosine kinase inhibitor demonstrating potent antiangiogenic properties indicated as monotherapy or combination therapy for certain malignancies. Lenvatinib is FDA-approved for radioactive iodine-refractory differentiated thyroid cancer (DTC), unresectable or advanced hepatocellular carcinoma (HCC), and advanced renal cell carcinoma (RCC).
Lenvatinib is orally available multi-kinase inhibitor and antineoplastic agent that is used in treatment of advanced, metastatic medullary thyroid cancer and refractory renal cell carcinoma. Lenvatinib is associated with a modest rate of serum enzyme elevations during treatment and has been implicated to rare instances of clinically apparent, acute liver injury some of which have been fatal.
Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors
Avoid hypertensive herbs (e.g. bayberry, blue cohosh, cayenne, ephedra, and licorice). Lenvatinib may cause hypertension as an adverse effect; therefore, there may be additive blood pressure elevation when using hypertensive herbs.
Take at the same time every day.

Synonyms

Lenvatinib; 417716-92-8; E7080; E-7080; E 7080; ER-203492-00; Kisplyx; 4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide; EE083865G2; CHEBI:85994; DTXSID50194605; 4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide; 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-CHLORO-4-((CYCLOPROPYLCARBAMOYL)AMINO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE; 6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)-7-METHOXY-

Frequently Asked Questions

What are the CAS number and molecular formula of Lenvatinib?

CAS 417716-92-8; molecular formula C21H19ClN4O4; molecular weight — g/mol.

What other names is Lenvatinib known by?

Lenvatinib, 417716-92-8, E7080, E-7080, E 7080, ER-203492-00.

Is Lenvatinib classified as hazardous?

Hazard statements reported: H302, H315, H319, H335, H361.

What are the key physical properties of Lenvatinib?

LogP: 3.3; Dissociation Constants: 5.05.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.